Notice of Allowability	Application No.	Applicant(s)
	10/788,996	STAPPER ET AL.
	Examiner	Art Unit
	Kamal A. Saeed	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to communication filed on 02/22/2007.		
2. The allowed claim(s) is/are 1-4, 6, 7, 16, and 24-26 now renumbered as 1-10.		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ol>		
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal P. 6. ☐ Interview Summary Paper No./Mail Dat 7. ☒ Examiner's Amendn 8. ☒ Examiner's Stateme 9. ☐ Other	(PTO-413), e

## **DETAILED ACTION**

Claims 1-26 are pending in this application. Claims 8-15 and 17-22 are withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference, which anticipates one group, would not render obvious the other.

## Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Authorization for this examiner's amendment was given in a telephone interview with Craig M. Bell on 03/30/2007.

The application has been amended as follows:

## Amendment to the Claims

In Claim 1, line 8, delete the terms ", pyridine, 1H-pyrrole, thiophene or furan"

In Claim 1, line 9, delete the term ", (C<sub>5</sub>.C<sub>11</sub>)-heteroaryl"

In Claim 3, page 6, line 12, delete the term ", (C<sub>5-</sub>C<sub>6</sub>)-heteroaryl"

In Claim 16, page 7, last line, delete the term ", (C<sub>5-</sub>C<sub>6</sub>)-heteroaryl"

Delete Claim 5.

Delete Claims 8-15 and 17-23.

Application/Control Number: 10/788,996

Art Unit: 1626

Any comments considered necessary by applicant must be submitted no later than the payment issue fee and, to avoid processing delays, should preferably accompany the issue fee.

Such submitions should be clearly labeled "Comments on Statement for Reasons for Allowance."

## **Reasons for Allowance**

The present invention is directed to compounds of Formula

as defined in claim 1. The closest prior

art is to Gretzke et al U.S. Patent No. 7,148,246 B2. Gretzke et al teach compounds of Formula

. The nonobvious aspect of the present invention is the

presence of the variables Y2 and ester or acid functional group. represents hydrogen. None of the published compounds anticipated, or rendered obvious, the compounds claimed in this application. Therefore, claims 1-4, 6, 7, 16 and 24-26 are allowable.

Any comments considered necessary by applicant must be submitted no later than the payment issue fee and, to avoid processing delays, should preferably accompany the issue fee.

Such submitions should be clearly labeled "Comments on Statement for Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal A Saeed whose telephone number is (571) 272-0705. The examiner can normally be reached on M-T 7:00 AM- 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signiture, may be used by applicant and should be addressed to [joseph.mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or public PAIR only. For more information about the

pair system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

KAMAL A. SAEED, PH.D PRIMARY EXAMINER